BidaskClub cut shares of West Pharmaceutical Services, Inc. (NYSE:WST) from a hold rating to a sell rating in a research note published on Thursday.

WST has been the subject of several other research reports. Zacks Investment Research raised shares of West Pharmaceutical Services from a hold rating to a buy rating and set a $108.00 price target for the company in a research note on Friday, June 23rd. Jefferies Group LLC reissued a hold rating and issued a $90.00 price target on shares of West Pharmaceutical Services in a research note on Thursday, June 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $90.18.

Shares of West Pharmaceutical Services (NYSE WST) opened at 89.55 on Thursday. The company has a market cap of $6.59 billion, a P/E ratio of 38.43 and a beta of 1.12. The firm has a 50-day moving average of $94.78 and a 200 day moving average of $88.69. West Pharmaceutical Services has a 52 week low of $70.17 and a 52 week high of $99.91.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.33%. The business had revenue of $397.60 million during the quarter, compared to analysts’ expectations of $406 million. During the same quarter in the prior year, the company posted $0.59 EPS. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. Equities analysts expect that West Pharmaceutical Services will post $2.73 EPS for the current fiscal year.

WARNING: “BidaskClub Downgrades West Pharmaceutical Services, Inc. (NYSE:WST) to Sell” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/bidaskclub-downgrades-west-pharmaceutical-services-inc-nysewst-to-sell/1463410.html.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be issued a $0.14 dividend. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 annualized dividend and a dividend yield of 0.63%. The ex-dividend date of this dividend is Tuesday, October 17th. West Pharmaceutical Services’s dividend payout ratio is currently 22.22%.

In other news, VP Daniel Malone sold 4,124 shares of the company’s stock in a transaction that occurred on Tuesday, May 2nd. The shares were sold at an average price of $93.31, for a total value of $384,810.44. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO William J. Federici sold 54,996 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $95.45, for a total transaction of $5,249,368.20. The disclosure for this sale can be found here. Corporate insiders own 1.90% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Burt Wealth Advisors raised its position in shares of West Pharmaceutical Services by 38,540.0% in the first quarter. Burt Wealth Advisors now owns 1,932 shares of the medical instruments supplier’s stock valued at $158,000 after buying an additional 1,927 shares in the last quarter. Harfst & Associates Inc. bought a new position in shares of West Pharmaceutical Services during the first quarter valued at approximately $186,000. CIBC Asset Management Inc bought a new position in shares of West Pharmaceutical Services during the second quarter valued at approximately $223,000. Tyers Asset Management LLC raised its position in shares of West Pharmaceutical Services by 17.6% in the first quarter. Tyers Asset Management LLC now owns 2,464 shares of the medical instruments supplier’s stock valued at $201,000 after buying an additional 368 shares in the last quarter. Finally, Cutler Group LP raised its position in shares of West Pharmaceutical Services by 482.2% in the second quarter. Cutler Group LP now owns 2,550 shares of the medical instruments supplier’s stock valued at $241,000 after buying an additional 2,112 shares in the last quarter. Hedge funds and other institutional investors own 91.34% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.